Effects of propofol and isoflurane on haemodynamics and the inflammatory response in cardiopulmonary bypass surgery.
Cardiopulmonary bypass (CPB) causes reperfusion injury that when most severe is clinically manifested as a systemic inflammatory response syndrome. The anaesthetic propofol may have anti-inflammatory properties that may reduce such a response. We hypothesised differing effects of propofol and isoflurane on inflammatory markers in patients having CBR Forty patients undergoing elective CPB were randomised to receive either propofol or isoflurane for maintenance of anaesthesia. CRP, IL-6, IL-8, HIF-1α (ELISA), CD11 and CD18 expression (flow cytometry), and haemoxygenase (HO-1) promoter polymorphisms (PCR/electrophoresis) were measured before anaesthetic induction, 4 hours post-CPB, and 24 hours later. There were no differences in the 4 hours changes in CRP, IL-6, IL-8 or CD18 between the two groups, but those in the propofol group had higher HIF-1α (P = 0.016) and lower CD11 expression (P = 0.026). After 24 hours, compared to the isoflurane group, the propofol group had significantly lower levels of CRP (P < 0.001), IL-6 (P < 0.001) and IL-8 (P < 0.001), with higher levels CD11 (P = 0.009) and CD18 (P = 0.002) expression. After 24 hours, patients on propofol had increased expression of shorter HO-1 GT(n) repeats than patients on isoflurane (P = 0.001). Use of propofol in CPB is associated with a less adverse inflammatory profile than is isofluorane, and an increased up-regulation of HO-1. This supports the hypothesis that propofol has anti-inflammatory activity.
S
S
Sayed
N K
NK
Idriss
H G
HG
Sayyedf
A A
AA
Ashry
D M
DM
Rafatt
A O
AO
Mohamed
A D
AD
Blann
D000328:Adult; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D018821:CD18 Antigens / Q000097:blood; D002315:Cardiopulmonary Bypass; D005260:Female; D051547:Heme Oxygenase-1 / Q000097:blood / Q000235:genetics; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007530:Isoflurane; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D015742:Propofol / Q000627:therapeutic use*; D017464:Receptors, Complement 3d / Q000097:blood; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D016896:Treatment Outcome
D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D018821:CD18 Antigens; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C508600:IL6 protein, human; D015850:Interleukin-6; D016209:Interleukin-8; D017464:Receptors, Complement 3d; D002097:C-Reactive Protein; D007530:Isoflurane; C496541:HMOX1 protein, human; D051547:Heme Oxygenase-1; D015742:Propofol